Company profile
Qyuns Therapeutics company profile
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.
Business identity
- Website
- https://www.qyuns.net/
- Phone number
- +86 0523-80276311
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 251-500 employees
- Revenue range
- $1M-$10M
- Founded
- 2015-01-01, Year
Headquarters
- Headquarters
- Taosi, Shanxi, China
- Postal code
- 225300
- Country code
- CN
- Continent
- Asia